Michel J.P. DuPage

MHCII+ cancer-associated fibroblasts promote antitumor immunity in pancreatic cancer

This study shows that MHCII+ cancer-associated fibroblasts (CAFs) in pancreatic cancer can promote antitumor immunity through IFNγ-driven mechanisms, counteracting Treg suppression.

Improved cross-presentation enabled by fusion-dependent mini-proteins that efficiently reach the dendritic cell cytosol

This study improves cross-presentation by using fusion-dependent mini-proteins to enhance antigen delivery to the dendritic cell cytosol, leading to better MHC-I presentation and T-cell activation.

Avoidance of MAIT cells is an essential determinant of Listeriamonocytogenes pathogenesis

This study shows that Listeria monocytogenes evades MAIT cells by lacking riboflavin biosynthesis, and engineered strains that produce riboflavin activate MAIT cells, offering therapeutic potential against infections and cancer.

Intra-Tumoral Treg Ablation Unleashes NK Cell-Mediated Control of CD8 T Cell-Resistant Tumors

Intra-tumoral Treg ablation enhances NK cell-mediated tumor control by restoring IL-2 production, effective against both MHC I+ and MHC I- cancers without systemic toxicity.

Selective disruption of lipid peroxide homeostasis in intratumoral regulatory T cells by targeting FSP1 enhances cancer immunity

This study shows targeting FSP1 in regulatory T cells disrupts their immunosuppression, enhancing anti-tumor immunity without causing autoimmunity.

Age-related remodeling of the glycocalyx drives T cell exhaustion

This study shows that aging reduces 2,6-linked sialic acids on T cells, leading to exhaustion and impaired immune function.

Epigenetically regulated p53 activity maintains intestinal regulatory T cell identity to prevent inflammation

This study shows that p53 activity, regulated epigenetically, maintains intestinal Treg identity and prevents inflammation by preventing Foxp3 loss in Th17 environments.

Intratumoral Treg ablation is sufficient to mediate tumor control systemically without autoimmunity

The paper shows that ablating tumor-infiltrating Tregs systemically controls tumors without autoimmunity, primarily through CD4+ T cells and cDC2s.

TLR2 signaling uniquely destabilizes tumor Tregs to promote cancer immunotherapy

This study shows that TLR2 signaling in innate immune cells within tumors reduces Treg stability, enhancing cancer immunotherapy by improving CD8+ T cell function.

Increased EZH2 function in regulatory T cells promotes their capacity to suppress autoimmunity by driving effector differentiation prior to activation

This study shows that increased EZH2 activity in regulatory T cells enhances their effector differentiation and autoimmunity suppression capacity.